• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Polycystic Kidney Disease: Studies on Obesity, Pain, Screening

Slideshow

Find summaries here of 3 recent studies conducted to shed light on difficult issues in the management of autosomal dominant polycystic kidney disease.

In the short slide show below you will find summaries of 3 recent studies conducted to shed light on difficult issues in the management of autosomal dominant polycystic kidney disease:
• The linkage of overweight/obesity to a marker of ADPKD severity and progression
• Real-world use of prescription medications for pain in patients with ADPKD
• Patient and caregiver perspectives on ADPKD genetic screening and testing 

Related Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

Grace Halsey
November 7th 2024
Article

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit ©Tada Images/stock.adobe.com

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

Grace Halsey
November 1st 2024
Article

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose / image credit: ©New Africa/AdobeStock

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose

Sydney Jennings
November 1st 2024
Article

Your daily dose of the clinical news you may have missed.

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024 / Image credit: ©Rasi/AdobeStock

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024

Sydney Jennings
October 23rd 2024
Article

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial / image credit heart and kidneys: ©krishnacreations/stock.adobe.com

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial

Grace Halsey
October 21st 2024
Article

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting / image credit kidneys concept ©Rasi/stock.adobe.com

Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting

Grace Halsey
October 14th 2024
Article

Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.

© 2025 MJH Life Sciences

All rights reserved.